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Background: Research on the relationship between urinary albumin excretion and serum cystatin C in diabetes is restricted to 
cross-sectional studies. In this study, we investigated how well serial measurements of serum cystatin C level reflect changes in 
the urinary albumin excretion rate. 
Methods: We enrolled and retrospectively collected data on 1,058 participants with type 2 diabetes who were older than 18 years 
and who had more than 3 years of follow-up with serial measurements of albuminuria and serum cystatin C at an outpatient 
clinic.
Results: With the use of a linear mixed model, we found that the albuminuria level for each patient over time corresponded with 
the annual change in serum cystatin C-based estimated glomerular filtration rate (cysC-eGFR) but did not correspond with the 
creatinine-based eGFR calculated by the modification of diet in renal disease formula (MDRD-eGFR). The discrepancy in the 
direction of the trend was smaller with cysC-eGFR than with MDRD-eGFR. 
Conclusion: Serum cystatin C level reflects the trend in albuminuria level more accurately than serum creatinine level in Kore-
an type 2 diabetes mellitus patients.
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INTRODUCTION
Most cases of end stage renal disease (ESRD) are caused by di-
abetes, and the number of cases has increased numerically and 
proportionally during the last few decades. Diabetic nephrop-
athy, which causes the adverse outcomes of kidney failure, car-
diovascular disease and premature death, is now the single most 
common cause of ESRD in both Western and Eastern coun-
tries [1]. However, our ability to assess early renal impairment 
in diabetic nephropathy, when active management is impor-
tant, is still poor in comparison to biomarker-based approach-
es for other diseases, such as serum troponin concentration in 
acute myocardial infarct [2].
 Serum creatinine level is the most commonly used surro-
gate measurement of glomerular filtration rate (GFR) in a 
clinical setting. In 2002, the Kidney Disease Outcomes Quality 
Initiative (K/DOQI) organization published guidelines for 
chronic kidney disease [3]. This classification, based on the 
modification of diet in renal disease (MDRD) study estimation 
equation for GFR using serum creatinine concentration, was 
immediately widely embraced [4]. However, serum creatinine 
concentration does not increase until renal function decreases 
to less than 50% of the normal value [5]. The variances accord-
ing to age, sex, physical exercise, and lean body mass are also 
important limitations [6]. Gold standard tests using radioiso-
topes such as 51Cr-labeled EDTA, 99mTc-labeled DTPA, and 
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125I-labeled iothalamate or iohexol [7,8] are most reliable for 
measurement of GFR but are too difficult to use in the clinic 
setting [9]. Therefore, an accurate and available marker of GFR 
for patients with diabetic nephropathy is needed. 
 In the past three decades, urinary albumin excretion has as-
sumed a central role in the diagnosis and management of kid-
ney disease among people with diabetes mellitus [2]. This led 
investigators during the early 1980s to search for early predic-
tors of diabetic nephropathy through the measurement of low 
concentrations of albumin in the urine, especially in type 1 di-
abetic patients [10,11]. Despite a great deal of controversy 
[4,12], microalbuminuria is now widely accepted as a predic-
tive marker of overt proteinuria [13] and increased cardiovas-
cular disease and mortality [14] not only in type 1 diabetes 
mellitus [15], but also in type 2 diabetic mellitus [13]. The im-
portance of albuminuria has increased in practice as well as in 
laboratory research.
 However, urinary albumin excretion can be affected by sev-
eral factors including plasma concentrations of atrial natriuret-
ic peptide, arginine vasopressin, angiotensin II, aldosterone 
and fasting blood glucose, glycated hemoglobin, and mean ar-
terial blood pressure [16] and albumin can be degraded in a 
manner consistent with the activity of endogenous urinary 
proteases [17]. Furthermore, the intraindividual variation is as 
high as 47%. Because of these problems, all results that are ini-
tially positive for albuminuria need to be confirmed with a 
second sample collected on a different day, and in cases of dis-
crepancies between the first and second sample, a third sample 
is necessary. Despite the convenience of urinary albumin/cre-
atinine ratio (uACR) measurement in random urine samples 
compared to 24-hour urine collection, it incommodes clini-
cians who provide primary care to diabetic patients and causes 
a delay in the recognition and initial treatment for diabetic ne-
phropathy. It is a fundamental problem because its main pur-
pose is the detection of diabetic nephropathy at an early stage. 
Therefore, while continuing to encourage the use of the K/
DOQI classification, which provides a well-established clinical 
guideline, the diabetology community should eagerly seek oth-
er methods to measure or better estimate early kidney damage 
of diabetic nephropathy, while maintaining the virtue of uACR. 
Further, changes in urinary albumin excretion are dynamic, 
whereas changes in GFR are usually progressive. Although in-
creases in urinary albumin excretion generally precede a de-
cline in GFR, some patients follow a non-albuminuric path-
way to renal impairment. Therefore, in the assessment of dia-
betic nephropathy, the roles of albuminuria and GFR are com-
plementary rather than competitive [18].
 Recently, cystatin C was introduced as a good marker of 
early renal function decline [19,20], particularly in diabetic 
[21] or elderly [22] patients. Cystatin C is being considered as 
a potential replacement for serum creatinine because it appears 
to be less affected by muscle mass [23], and most studies have 
shown that it is more highly correlated with GFR than is serum 
creatinine [20,24]. Furthermore, there is no interference from 
metabolites, like bilirubin, ketones, and various drugs like an-
tidiabetic medications [25]. Cystatin C is a non-glycosylated 
protein belonging to the super family of cysteine protease in-
hibitors, and it is produced by all nucleated cells at a constant 
rate [26]. Serum cystatin C fulfills a number of the criteria that 
would make it a suitable marker of GFR. It can be freely filtered 
at the glomerular membrane because of a low molecular weight 
(Mr=13359) [9] and reabsorbed and catabolized by renal tu-
bular cells [27]. Furthermore, its concentration is stable in 
stored plasma, unlike urinary albumin, probably due to the 
high concentration of other proteinase inhibitors [28]. Perkins 
et al. [29] reported longitudinal data demonstrating that the 
change in 100/cystatin C was more accurately correlated with 
the change in iothalamate-GFR than with the change in esti-
mated GFR (eGFR) as calculated from serum creatinine.
 Some studies have investigated the correlation between al-
buminuria and serum cystatin C level, but they evaluated se-
rum cystatin C and albuminuria in cross-sectional datasets 
[30,31]. Therefore, we analyzed the longitudinal correlation 
between cystatin C and albuminuria in Korean patients with 
type 2 diabetes mellitus.
METHODS
Subjects
We collected and retrospectively reviewed the medical records 
of 1,058 subjects with type 2 diabetes mellitus who visited the 
out-patient department of the Endocrinology and Metabolism 
Division at Yonsei University, Gangnam Severance Hospital, 
Seoul, South Korea from March 2006 to March 2010 (Fig. 1). 
Inclusion criteria were as follows: 1) previously known type 2 
diabetic mellitus; 2) more than 3 years of follow-up for serum 
creatinine, cystatin C, and uACR; and 3) age between 18 and 
85 years. Subjects were excluded if they had 1) significant he-
patic disease (alanine aminotransferase or aspartate amino-
transferase >2.5-fold the normal value); 2) thyroid disease or 
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medication due to thyroid disease during the previous six 
months; 3) any other medical condition that could alter the 
level of serum cystatin C or uACR; or 4) if they were pregnant. 
The subjects were classified into three groups, according to 
uACR: 1) normoalbuminuria group (uACR <30 μg/mg); 2) 
microalbuminuria group (30 μg/mg≤uACR<300 μg/mg); 
and 3) overt albuminuria group (uACR≥300 μg/mg Cr). Obe-
sity was defined according to 2000 WHO criteria, the Asia-Pa-
cific perspective, as follows; 1) normal weight (body mass in-
dex [BMI] <23 kg/m2); 2) overweight (23 kg/m2≤BMI<25 
kg/m2); 3) obese (BMI≥25 kg/m2). This study was approved 
by our human research ethics committee. 
Study design
BMI was calculated as body weight in kilograms divided by 
height in meters squared (kg/m2). Hypertension was defined 
as systolic blood pressure (SBP) ≥140 mm Hg or diastolic blood 
pressure (DBP) ≥90 mm Hg and/or reported treatment with 
antihypertensive medications in the previous 2 weeks. SBP 
and DBP values were classified by the Joint National Commit-
tee (JNC) 7 report in 2003.
 Blood was sampled from all of the subjects after fasting for 
more than 10 hours, and random urine was collected. Serum 
cystatin C was measured by latex particle-enhanced turbidi-
metric immunoassays (Cobas 6000 analyzer; Roche Diagnos-
tics, West Sussex, UK). Serum and urine creatinine levels were 
measured by automatic picric colorimetry (Hitachi 7600-110 
automatic analyzer; Hitachi Co., Tokyo, Japan). Hemoglobin 
A1c (HbA1c) was determined by means of high-performance 
liquid chromatography (Variant II; Bio-Rad, Hercules, CA, 
USA). Total cholesterol (TC), triacylglyceride (TG), and high 
density lipoprotein cholesterol (HDL-C) levels were measured 
by an enzymatic method using an enzymatic color test (747 
automatic analyzer; Hitachi Co., Tokyo, Japan), and low densi-
ty lipoprotein cholesterol (LDL-C) was calculated according to 
Friedewald’s formula.
The estimated GFR level was calculated using the MDRD 
formula (MDRD-eGFR) [32]: 
MDRD-eGFR=186×(serum creatinine [mg/dL])-1.154
×age-0.203×(0.742 if female)
The cystatin C-based estimated GFR (CysC-eGFR) equation 
[33]:
CysC-eGFR=78/ (serum cystatin C in mg/L)+4
 To compare the change in variables over three years, we cal-
culated the initial and last value of cysC-eGFR and MDRD-
eGFR using two different approaches, as follows:
1) Simple subtraction
A. ΔcysC-eGFR=last cysC-eGFR–initial cysC-eGFR
B.  ΔMDRD-eGFR=last MDRD-eGFR–initial MDRD-
eGFR
2) Declining slope
A.  cysC-eGFR change rate=ΔcysC-eGFR/initial cys-eG-
FR
B.  MDRD-eGFR change rate=ΔMDRD-eGFR/initial 
MDRD-eGFR
Statistical analysis
All statistical analyses were performed using SPSS version 18.0 
(IBM, Chicago, IL, USA), except for the generalized linear 
mixed model for longitudinal analysis, which was performed 
using SAS version 9.0 (SAS Institute Inc., Cary, NC, USA). Se-
rum cystatin C and creatinine concentration were transformed 
to the reciprocal by multiplying by 100 for analysis. This trans-
formation was performed to assure that changes over time had 
the same direction as the changes in estimated GFR calculated 
using the MDRD formula. Descriptive data are expressed as 
mean±standard deviation, but in the generalized linear mixed 
model, we used standard error instead of standard deviation. 
P values less than 0.05 were considered statistically significant.
1,058 subjects screened in March 2006
787 subjects with type 2 diabetes mellitus in 2006
264 subjects were remained in 2010
271 subjects were excluded in 2006 due to 
Significant hepatic disease  76
Thyroid disease or medication 17
Other medical condition 169
Pregnancy 9
Follow-up for 4 yr
206 subjects: follow-up loss
319 subjects: data collection missing
Fig. 1. Selection of study participants.
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RESULTS
Clinical and biochemical characteristics of subjects
The clinical characteristics of the study subjects are shown in 
Table 1. The group of 264 subjects was male-dominant, with 
an average age of 61.8±10.6 years in the baseline period. The 
subjects were followed for three years. The proportion of el-
derly subjects, defined as older than 65 years, constituted al-
most half of the study group. The mean BMI of these subjects, 
24.2±3.0 kg/m2, was in the overweight range, although fewer 
than 10% of the subjects were obese. Two-thirds of the sub-
jects were prescribed angiotensin-converting enzyme inhibi-
tors and/or angiotension receptor blocker as antihypertensive 
drugs, and their blood pressures were under control. The mean 
fasting glucose level of the subjects, 131.1±65.7 mg/dL, was 
relatively high, but only one-sixth of the patients had an HbA1c 
greater than 9%, indicating that, overall, the blood sugar levels 
were under control in this study group. 
 The mean uACR of subjects was in the microalbuminuria 
range, and all stages of albuminuria were included. Patients in 
the nephritic range of proteinuria greater than 2 g/day were 
excluded because the possibility of other kidney disease could 
not be eliminated. The portion of patients with renal failure, 
defined as an eGFR lower than 60 mL/min/1.73 m2, was almost 
half of the study group. However, if eGFR was calculated using 
a cystatin C-based equation rather than the MDRD formula, 
the portion decreased to 34.3%. Patients with end stage renal 
failure were not included because their status of albuminuria 
could not be interpreted properly since their urinary albumin 
was not only glomerular in origin, but also tubular, and some 
of them had an anuric status.
Longitudinal trends in uACR and renal function marker
As a result of longitudinal analysis using a general linear mixed 
model, only 100/cystatin C significantly affected uACR (P=
0.0407), while 100/serum creatinine and MDRD-eGFR did 
not. Serum cystatin C and creatinine values were transformed 
to the reciprocal multiplied by 100 to assure that changes over 
time had the same direction as changes in MDRD-eGFR. 
CysC-eGFR was not involved in this analysis because, unlike 
MDRD-eGFR, its equation has no other variables except se-
rum cystatin C. uACR decreased to 4.8321 mg/g when 100/
cystatin C increased to 1 L/mg (Table 2). Even after adjust-
ment for age, sex, serum uric acid, and HbA1c, these results 
did not change (P=0.0106); however, the other two renal 
Table 1. Baseline clinical and biochemical characteristics of 
the 264 subjects
Characteristic Initial, % After 3 yr, %
Age, yr 61.8±10.6
Older than 65 yr, % 44.3
Gender, male 72.2
Duration of diabetes 12.4±10.1
≤10 yr 45.3
>10 yr 54.7
BMI, kg/m² 24.2±3.0
Normal weight (BMI<23 kg/m2) 44.7
Overweight (23 kg/m2≤BMI<25 kg/m2) 48.0
Obesity (BMI≥25 kg/m2) 8.3
SBP, mm Hg 125.4±16.8
DBP, mm Hg 75.0±12.5
ACEi and/or ARB user, % 69.1
Serum uric acid, mg/dL 5.7±1.5
Total cholesterol, mg/dL 169.1±37.4
Triacylglyceride, mg/dL 161.3±127.7
HDL-C, mg/dL 45.0±12.8
LDL-C, mg/dL 97.5±32.8
Fasting glucose, mg/dL 131.1±65.7
HbA1c, % 7.7±1.5
HbA1c<7.0% 56.1
7.0%≤HbA1c<9% 27.4
HbA1c≥9% 16.5
uACR, mg/gCr 251.4±421.1 277.4±441.0
Normoalbuminuria, % 37.6 39.2
Microalbuminuria, % 38.9 36.1
Macroalbuminuria, % 23.6 24.7
Serum creatinine, mg/dL 1.53±1.4 1.49±1.3
MDRD-eGFR, mL/min/1.73 m2 61.5±24.8 60.5±24.0
eGFR≥60 mL/min/1.73 m2 51.3 55.4
eGFR<60 mL/min/1.73 m2 48.7 44.6
Serum cystatin C, mg/dL 1.32±0.72 1.26±0.61
CysC-eGFR 74.6±28.3 1.26±0.61
eGFR≥60 mL/min/1.73 m2 65.6 71.5
eGFR<60 mL/min/1.73 m2 34.3 28.5
Values are presented as mean±standard deviation or percentage.
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; ACEi, angiotension-converting enzyme inhibitors; 
ARB, angiotension receptor blocker; uACR, urine albumin/creatinine 
ratio; HDL-C, high density lipoprotein cholesterol; LDL-C, low densi-
ty lipoprotein cholesterol; MDRD-eGFR, estimated glomerular filtra-
tion rate calculated using the modification of diet in renal disease for-
mula; CysC-eGFR, estimated glomerular filtration rate calculated us-
ing serum cystatin C.
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function markers did not show any effect at all (Table 3). This 
result was consistent, regardless of the stage of chronic kidney 
disease stage.
 Additionally, age and serum uric acid concentration showed 
a significant correlation with uACR in serial measurement (P 
value=0.0023 and 0.027, respectively), although gender and 
HbA1c did not (P=0.1137, 0.4063, and 0.7372, respectively).
Accordance between uACR and cysC-eGFR or MDRD-
eGFR
CysC-eGFR showed better direction accordance (39.4%) with 
uACR in comparison to MDRD-eGFR (23.8%) (Fig. 2) when 
analyzing declining slope. When we used the simple subtrac-
tion value (Fig. 3), the accordance with uACR increased in 
both cases (52.3% and 36.8%, respectively), although that of 
cysC-eGFR was superior. When we categorized the linear 
variables according to the K/DOQI classification, the accor-
dance rate with uACR was 46.5% in the case of cys-eGFR and 
36.1% in the case of MDRD-eGFR. A close look at the discor-
dance portion revealed that cysC-eGFR was worse than 
MDRD-eGFR at detecting aggravation of albuminuria, and 
that MDRD-eGFR was worse than cysC-eGFRat detecting 
improvement in albuminuria or preservation status.
DISCUSSION
In our 3-year follow-up of a hospital cohort of type 2 diabetic 
patients, neither serum creatinine nor MDRD-eGFR corre-
sponded with the trend in uACR change (Tables 1 and 2). This 
result indicates that the underlying pathophysiology of albu-
Table 2. The effect of each variable on urinary albumin/creati-
nine ratio change analyzed by generalized linear mixed model
Parameter Estimate SE P value
Time, day 0.2358 0.1400 0.0957
100/serum cystatin C -4.8321 2.3309 0.0407
100/serum creatinine -11.1506 5.8248 0.0577
MDRD-eGFR 10.7033 7.0592 0.1318
Unadjusted for confounding variables.
SE, standard errors; MDRD-eGFR, estimated glomerular filtration 
rate calculated by the modification of diet in renal disease formula. 
Table 3. The effect of each variable on urinary albumin/creati-
nine ratio change analyzed by generalized linear mixed model
Parameter Estimate SE P value
Time, day 0.2437 0.1522 0.1137
Age, yr -31.4470 9.4526 0.0023
Gender, male -333.55 395.97 0.4063
Serum uric acid -75.8817 23.6904 0.0273
HbA1c -9.6286 28.4305 0.7372
100/serum cystatin C -7.3863 2.8093 0.0106
100/serum creatinine -14.1730 16.1013 0.3857
MDRD-eGFR 6.5659 18.3472 0.7229
CKD stage -151.51 149.94 0.3204
Adjusted for age, sex, serum uric acid, HbA1c.
SE, standard errors; MDRD-eGFR, estimated glomerular filtration 
rate calculated by the modification of diet in renal disease formula; 
CKD, chronic kidney disease. 
Fig. 2. Accordance of change rate between urinary albumin/creatinine ratio and estimated glumerular filtration rate (eGFR) cal-
culated by (A) modification of diet in renal disease (MDRD) formula or (B) serum cystatin C. Trend accordance (percent of sub-
jects in white box) is 23.8% in (A) and 39.4% in (B). 
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Table 4. Accordance of stage change between uACR and cysC-
eGFR or MDRD-eGFR using simple subtraction
Accordance, %
Discordance, %
Improved or 
preserved albu-
minuria stage
Aggravated  
albuminuria 
stage
cysC-eGFR 46.5 20.6 32.9
MDRD-eGFR 36.1 44.5 19.4
uACR, urine albumin/creatinine ratio; eGFR, estimated glomerular 
filtration rate; MDRD, modification of diet in renal disease; cysC-eG-
FR, eGFR calculated using serum cystatin C; MDRD-eGFR, eGFR 
calculated using MDRD formula.
portion was nearly half of all subjects (Table 4), so serum cys-
tatin C alone might have limited value as a replacement for 
uACR measurement.
 There are some controversies about the usefulness of serum 
cystatin C. Many studies have shown that serum cystatin C is a 
better predictor of cardiovascular disease, renal function [31] 
and mortality than is the serum creatinine-based eGFR for-
mula [34], although some researchers disagree with this con-
clusion [21]. The discordance comes from the difference in 
subject characteristics, mostly with regard to the mean age of 
the population or proportion of renal failure patients. Our study 
population was evenly distributed in terms of age and chronic 
kidney disease stage, thus reinforcing the reliability of our data. 
It is critical that the ideal marker of diabetic nephropathy not 
be limited to a certain stage of kidney disease or specific age 
group because diabetic nephropathy progresses throughout 
the entire life of diabetic patients and has a broad spectrum 
Fig. 3. Accordance of change between urinary albumin/creatinine ratio and estimated glumerular filtration rate (eGFR) calculat-
ed by (A) modification of diet in renal disease (MDRD) formula or (B) serum cystatin C. Trend accordance (percent of subjects 
in white box) is 36.8% in (A) and 52.3% in (B). 
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minuria and GFR loss are different in the early stages of dia-
betic kidney disease [27], and overt albuminuria does not al-
ways precede a significant loss of GFR in the setting of diabe-
tes. Therefore, measuring albuminuria alone does not fully 
capture the scope of early diabetic kidney disease [10,12]. In-
stead, albuminuria and GFR loss may represent complemen-
tary, if overlapping, manifestations of kidney damage [2]. 
 Most recent studies that have assessed serum cystatin C as a 
measure of GFR have been cross-sectional in nature, but lon-
gitudinal studies are needed to further define the potential role 
of cystatin C in clinical care [29]. Serum cystatin C has great 
advantages compared to inconvenient uACR measurements, 
as mentioned above. Furthermore, there is evidence that cysC-
eGFR is more valuable than MDRD-eGFR in the prediction of 
microalbuminuric stage in a cross-sectional clinical study of 
Korean type 2 diabetic patients [31]. To our knowledge, this is 
the first study to suggest a correlation between serum cystatin 
C and uACR in longitudinal studies for Korean type 2 diabetic 
patients. In contrast to serum creatinine and MDRD-eGFR, 
100/serum cystatin C showed a statistically significant correla-
tion with the trend of albuminuria (estimate -4.8321±2.2339, 
P=0.0407) (Table 2). Rather, the effect of 100/serum cystatin 
C on albuminuria increased after adjustments for age, sex, se-
rum uric acid concentration and glycated hemoglobin (esti-
mate -7.6667±2.8110, P=0.0106). However, the effects of 100/
serum creatinine (P=0.3857) and MDRD-eGRF (P=0.7229) 
on uACR remained insignificant (Table 3).
 In our study, we demonstrated the superiority of cysC-eG-
FR in reflecting the trend of albuminuria. But, the discordance 
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from incipient nephropathy to end stage renal disease, which 
requires dialysis.
 The limitations of our study are its retrospective design, the 
relatively small number of subjects and the fact that the data 
were collected from a single institute. Additional well-designed, 
prospective, and multicenter studies with a large population 
are required in the future.
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